Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Oral Investigations
Published in: Clinical Oral Investigations 7/2017

01-09-2017 | Original Article

Opiorphin in burning mouth syndrome patients: a case-control study

Authors: Ivan Salarić, Maja Sabalić, Ivan Alajbeg

Published in: Clinical Oral Investigations | Issue 7/2017

Login to get access

Abstract

Objectives

Opiorphin is a pentapeptide isolated from human saliva that suppresses pain from chemically induced inflammation and acute physical pain. Burning mouth syndrome (BMS) is a chronic condition of a burning sensation in the mouth, where no underlying dental or medical cause can be identified. We aimed to measure the level of opiorphin in whole unstimulated (UWS) and stimulated (SWS) saliva of patients with BMS.

Materials and methods

Originally developed and validated LC-MS/MS method was used for opiorphin quantification. Samples were obtained from 29 BMS patients and 29 age- and sex-matched controls.

Results

The average concentration of opiorphin in UWS and SWS in the BMS group was 8.13 ± 6.45 and 5.82 ± 3.59 ng/ml, respectively. Opiorphin in BMS patients’ UWS was significantly higher, compared to the control group (t = 2.5898; p = 0.0122). SWS opiorphin levels were higher, but not significantly, in BMS patients than in controls.

Conclusions

Our results indicate that higher quantities of salivary opiorphin in BMS may be a consequence of chronic pain, but we cannot exclude that they occur as a result of emotional and behavioral imbalances possibly associated with BMS. To our knowledge, this is the first original article measuring opiorphin in a pain disorder.

Clinical relevance

Opiorphin may be a measurable biomarker for chronic pain, which could help in objectifying otherwise exclusively a subjective experience. Increased opiorphin could serve as a universal objective indicator of painful conditions. Since opiorphin may also reflect emotional and socio-relational imbalances occurring with BMS, it could as well represent a biomarker for BMS. Knowledge on opiorphin’s involvement in pain pathways could contribute to developing new clinical diagnostic methods for BMS.
Literature
1.
Wisner A, Dufour E, Messaoudi M, Nejdi A, Marcel A, Ungeheuer MN, Rougeot C (2006) Human opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci U S A 103:17979–17984CrossRefPubMedPubMedCentral
2.
Rougeot C, Robert F, Menz L, Bisson JF, Messaoudi M (2010) Systemically active human opiorphin is a potent yet non-addictive analgesic without drug tolerance effects. J Physiol Pharmacol 61:483–490PubMed
3.
Javelot H, Messaoudi M, Garnier S, Rougeot C (2010) Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways. J Physiol Pharmacol 61:355–362PubMed
4.
Popik P, Kamysz E, Kreczko J, Wróbel M (2010) Human opiorphin: the lack of physiological dependence, tolerance to antinociceptive effects and abuse liability in laboratory mice. Behav Brain Res 213:88–93CrossRefPubMed
5.
Yang QZ, SS L, Tian XZ, Yang AM, Ge WW, Chen Q (2011) The antidepressant-like effect of human opiorphin via opioid-dependent pathways in mice. Neurosci Lett 489:131–135CrossRefPubMed
6.
Tian XZ, Chen J, Xiong W, He T, Chen Q (2009) Effects and underlying mechanisms of human opiorphin on colonic motility and nociception in mice. Peptides 30:1348–1354CrossRefPubMed
7.
Kamysz E, Sałaga M, Sobczak M, Kamysz W, Fichna J (2013) Characterization of the effects of opiorphin and sialorphin and their analogs substituted in position 1 with pyroglutamic acid on motility in the mouse ileum. J Pept Sci 19:166–172CrossRefPubMed
8.
Dufour E, Villard-Saussine S, Mellon V, Leandri R, Jouannet P, Ungeheuer MN, Rougeot C (2013) Opiorphin secretion pattern in healthy volunteers: gender difference and organ specificity. Biochem Anal Biochem 2:136. doi:10.​4172/​2161-1009.​1000136
9.
Rougeot C (2014) Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases. US patent US8642729 B2
10.
Al-Saffar MT, Al-Sandook TA, Y-Taha M (2013) A possible new concept in the mechanism of action of local anesthesia. Am J Med Biol Res 1:134–137CrossRef
11.
Headache Classification Subcommittee of the International Headache Society (2013) The international classification of headache disorders: 3rd edition. Cephalalgia 33:629–808CrossRef
12.
13.
Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA (2003) Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 14:275–291CrossRefPubMed
14.
Grushka M, Ching V, Epstein V (2006) Burning mouth syndrome. Adv Othorinolaryngol 63:278–287
15.
Forsell H, Jääakeläinen S, Tenovuo O, Hinkka S (2002) Sensory dysfunction in burning mouth syndrome. Pain 99:41–47CrossRef
16.
Hagelberg N, Forsell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, Luutonen S, Någren K, Jääskeläinen S (2003) Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 101:149–154CrossRefPubMed
17.
Nagler RM, Hershkovich O (2004) Sialochemical and gustatory analysis in patients with oral sensory complaints. J Pain 5:56–63CrossRefPubMed
18.
Granot M, Nagler RM (2005) Association between regional idiopathic neuropathy and salivary involvement as the possible mechanism for oral sensory complaints. J Pain 6:581–587CrossRefPubMed
19.
Jääskeläinen SK (2012) Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol 123:71–77CrossRefPubMed
20.
Sabalić M, Brkljačić L, Salarić I, Alajbeg I, Jerić I, Nemet I (2012) Salivary opiorphin as a potential marker of oral disease. Book of abstracts of the 11th Biennial Congress of the European Association of Oral Medicine. Oral Dis 18(1, SI):21
21.
Brkljačić L, Sabalić M, Salarić I, Jerić I, Alajbeg I, Nemet I (2011) Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantification of opiorphin in human saliva. J Chromatogr B Analyt Technol Biomed Life Sci 879:3920–3926CrossRefPubMed
22.
23.
24.
Netto FO, Diniz IM, Grossmann SM, de Abreu MH, do Carmo MA, Aguiar MC (2011) Risk factors in burning mouth syndrome: a case-control study based on patient records. Clin Oral Investig 15:571–575CrossRefPubMed
25.
26.
Bergdahl M, Bergdahl J (1999) Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med 28:350–354CrossRefPubMed
27.
Lopez-Jornet P, Molino Pagan D, Andujar Mateos P, Rodriguez Agudo C, Pons-Fuster A (2015) Circadian rhythms variation of pain in burning mouth syndrome. Geriatr Gerontol Int 15:490–495. doi:10.​1111/​ggi.​12303 CrossRefPubMed
28.
Morris KE, St Laurent CD, Hoeve RS, Forsythe P, Suresh MR, Mathison RD, Befus AD (2009) Autonomic nervous system regulates secretion of anti-inflammatory prohormone SMR1 from rat salivary glands. Am J Physiol Cell Physiol 296:C514–C524CrossRefPubMed
29.
Heckmann SM, Heckmann JG, HiIz MJ, Popp M, Marthol H, Neundörfer B, Hummel T (2001) Oral mucosal blood flow in patients with burning mouth syndrome. Pain 90:281–286CrossRefPubMed
30.
Ran HH, Zhang R (2011) Renin-angiotensin system modulates vasoreactivity through a mechanism of oxidative stress. Sheng Li Ke Xue Jin Zhan 42:117–120PubMed
31.
Fang Y, Li S, Zhou H, Tian X, Lv S, Chen Q (2014) Opiorphin increases blood pressure of conscious rats through renin-angiotensin system (RAS). Peptides 55C:47–51CrossRef
32.
Tian XZ, Chen Y, Bai L, Luo P, XJ D, Chen Q, Tian XM (2015) Effects and underlying mechanisms of human opiorphin on cardiovascular activity in anesthetized rats. Eur J Pharmacol 749:32–38CrossRefPubMed
33.
Salort-Llorca C, Mínguez-Serra MP, Silvestre FJ (2008) Drug-induced burning mouth syndrome: a new etiological diagnosis. Med Oral Patol Oral Cir Bucal 13:E167–E170PubMed
34.
Mathison R, Davison JS, Befus AD (1994) Neuroendocrine regulation of inflammation and tissue repair by submandibular gland factors. Immunol Today 15:527–532CrossRefPubMed
35.
Mathison RD, Davison JS, St Laurent CD, Befus AD (2012) Autonomic regulation of anti-inflammatory activities from salivary glands. Chem Immunol Allergy 98:176–195CrossRefPubMed
36.
Mathison RD, Davison JS, Befus AD, Gingerich DA (2010) Salivary gland derived peptides as a new class of anti-inflammatory agents: review of preclinical pharmacology of C-terminal peptides of SMR1 protein. J Inflamm (Lond) 7:49CrossRef
37.
Rosinski-Chupin I, Huaulme JF, Rougeot C, Rougeon F (2001) The transcriptional response to androgens of the rat VCSA1 gene is amplified by both binary and graded mechanisms. Endocrinology 142:4550–4559CrossRefPubMed
38.
Woda A, Dao T, Gremeau-Richard C (2009) Steroid dysregulation and stomatodynia (burning mouth syndrome). J Orofac Pain 23:202–210PubMed
39.
Kim HI, Kim YY, Chng JY, Ko JY, Kho HS (2012) Salivary cortisol, 17β-estradiol, progesterone, dehydroepiandrosterone, and α-amylase in patients with burning mouth syndrome. Oral Dis 18:613–620CrossRefPubMed
40.
Trombelli L, Mandrioli S, Zangari F, Saletti C, Calura G (1992) Oral symptoms in the climacteric. A prevalence study. Minerva Stomatol 41:507–513PubMed
41.
Srivastava A, Wang J, Zhou H, Melvin JE, Wong DT (2008) Age and gender related differences in human parotid gland gene expression. Arch Oral Biol 53:1058–1070CrossRefPubMedPubMedCentral
Metadata
Title
Opiorphin in burning mouth syndrome patients: a case-control study
Authors
Ivan Salarić
Maja Sabalić
Ivan Alajbeg
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 7/2017
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-016-2031-9

Other articles of this Issue 7/2017

Clinical Oral Investigations 7/2017 Go to the issue

Original Article

Effects of enamel matrix derivative on non-surgical management of peri-implant mucositis: a double-blind randomized clinical trial

Original Article

Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study

Letter to the Editor

Was molar-incisor hypomineralisation (MIH) present in archeological case series?

Original Article

Impact of abutment material on peri-implant soft tissue color. An in vitro study

Original Article

Lipoid proteinosis unveiled by oral mucosal lesions: a comprehensive analysis of 137 cases

Original Article

Effectiveness of pit and fissure sealants bonded with different adhesive systems: a prospective randomized controlled trial